---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-122774"
form_type: "8-K"
ticker: "MAZE"
cik: "0001842295"
company_name: "Maze Therapeutics, Inc."
filed_at: "2026-03-25T23:59:59+00:00"
generated_at: "2026-05-15T09:03:44.540428+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Maze Q4 net loss $34.6M; MZE829 Phase 2 35.6% uACR drop; Neil Kumar joins board

## Summary
- Net loss $34.6M in Q4, $131.1M for FY2025; cash $360M provides runway into 2028.
- MZE829 Phase 2 HORIZON: mean uACR reduction 35.6% at week 12; 50% patients >30% reduction.
- FSGS subgroup 61.8% mean uACR reduction; non-diabetic AMKD 48.6%; well-tolerated, no serious AEs.
- Neil Kumar (BridgeBio CEO) appointed to board effective March 27, 2026; receives option grant.
- Plans to advance MZE829 to pivotal program; MZE782 Phase 2 trials in PKU and CKD expected in 2026.

## SEC filing metadata
- accession: 0001193125-26-122774
- form_type: 8-K
- ticker: MAZE
- cik: 0001842295
- company_name: Maze Therapeutics, Inc.
- filed_at: 2026-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/0001193125-26-122774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/maze-20260324.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-122774
- JSON: https://secwatch.observer/filing/0001193125-26-122774.json
- Plain text: https://secwatch.observer/filing/0001193125-26-122774.txt

## Key facts
- Earnings Releases
  Maze Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2025.
  - Period: the fourth quarter and year ended December 31, 2025
  - Result: reported results
  source text: On March 25, 2026, Maze Therapeutics Inc. (the “Company”) issued a press release reporting its financial results for the fourth quarter and year ended December 31, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1842295/000119312526122774/0001193125-26-122774-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.